Sign in Sign up for free

Last updated: 29 January 2021 at 7:54pm EST

Gerald McMahon Net Worth




The estimated Net Worth of Gerald Ph D Mc Mahon is at least $5.76 Million dollars as of 5 June 2019. Gerald Mahon owns over 169,462 units of Harpoon Therapeutics stock worth over $3,968,351 and over the last 8 years he sold HARP stock worth over $0. In addition, he makes $1,793,260 as President, Chief Executive Officer, and Director at Harpoon Therapeutics.

Gerald McMahon HARP stock SEC Form 4 insiders trading

Gerald has made over 4 trades of the Harpoon Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 169,462 units of HARP stock worth $101,677 on 5 June 2019.

The largest trade he's ever made was exercising 169,462 units of Harpoon Therapeutics stock on 5 June 2019 worth over $101,677. On average, Gerald trades about 5,563 units every 1 days since 2016. As of 5 June 2019 he still owns at least 172,462 units of Harpoon Therapeutics stock.

You can see the complete history of Gerald Mahon stock trades at the bottom of the page.





Gerald McMahon biography

Dr. Gerald (Jerry) McMahon Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. McMahon was the President and Chief Executive Officer of Kolltan Pharmaceuticals, Inc., an oncology biologics company where he played a key role in the development of the business. From October 2010 to May 2012, he served as Senior Vice President of Oncology at MedImmune LLC, a subsidiary of AstraZeneca. Prior to MedImmune, he served as the Chairman and Chief Executive Officer of NeoRx Corporation, a pharmaceutical company, and as a venture partner at Bay City Capital, a venture capital firm, and in executive leadership roles at Poniard Pharmaceuticals and SUGEN (acquired by Pfizer), both biopharmaceutical companies, where he was a key player in the development and commercialization of innovative oncology drugs. Dr. McMahon earned a B.S. in Biology and a Ph.D. in Biochemistry from the Rensselaer Polytechnic Institute. He holds an academic appointment at the Yale Comprehensive Cancer Center at Yale University, and previously held post-graduate appointments at Tufts University School of Medicine, department of hematology and oncology at the New England Medical Center, and the Massachusetts Institute of Technology. Our Board believes that Dr. McMahon’s expertise and experience as our President and Chief Executive Officer, his depth and expertise in the life sciences industry, his experience in leadership, scientific innovation and creative deal-making and his educational background provide him with the qualifications and skills to serve on our Board.

What is the salary of Gerald McMahon?

As the President, Chief Executive Officer, and Director of Harpoon Therapeutics, the total compensation of Gerald McMahon at Harpoon Therapeutics is $1,793,260. There are no executives at Harpoon Therapeutics getting paid more.



How old is Gerald McMahon?

Gerald McMahon is 65, he's been the President, Chief Executive Officer, and Director of Harpoon Therapeutics since 2016. There are no older and 14 younger executives at Harpoon Therapeutics.

Insiders trading at Harpoon Therapeutics

Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt, and Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.



What does Harpoon Therapeutics do?

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.



What does Harpoon Therapeutics's logo look like?

Harpoon Therapeutics, Inc. logo

Complete history of Gerald Mahon stock trades at Celldex Therapeutics and Harpoon Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
5 Jun 2019 HARP Harpoon Therapeutics, Inc. Gerald Ph D Mc Mahon
President and CEO
 Option 169,462 $0.60 $101,677
5 Jun 2019
172,462 ↗
14 May 2019 HARP Harpoon Therapeutics, Inc. Gerald Ph D Mc Mahon
President and CEO
 Buy 1,000 $10.16 $10,160
14 May 2019
3,000 ↗
8 May 2019 HARP Harpoon Therapeutics, Inc. Gerald Ph D Mc Mahon
President and CEO
 Buy 1,000 $10.56 $10,560
8 May 2019
2,000 ↗
3 May 2019 HARP Harpoon Therapeutics, Inc. Gerald Ph D Mc Mahon
President and CEO
 Buy 1,000 $10.53 $10,530
3 May 2019
1,000 ↗


Harpoon Therapeutics executives and stock owners

Harpoon Therapeutics executives and other stock owners filed with the SEC include: